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Although initial presentation has been commonly used to select empirical therapy in patients with community-
acquired pneumonia (CAP), few studies have provided a quantitative estimation of its value. The objective of this
study was to analyse whether a combination of basic clinical and laboratory information performed at bedside can
accurately predict the aetiology of pneumonia.
A prospective study was developed among patients admitted to the Emergency Department University Hospital
Arnau de Vilanova, Lleida, Spain, with CAP. Informed consent was obtained from patients in the study. At entry,
basic clinical (age, comorbidity, symptoms and physical findings) and laboratory (white blood cell count)
information commonly used by clinicians in the management of respiratory infections, was recorded. According to
microbiological results, patients were assigned to the following categories: bacterial (Streptococcus pneumoniae and
other pyogenic bacteria), virus-like (Mycoplasma pneumoniae, Chlamydia spp and virus) and unknown pneumonia.
A scoring system to identify the aetiology was derived from the odds ratio (OR) assigned to independent variables,
adjusted by a logistic regression model. The accuracy of the prediction rule was tested by using receiver operating
characteristic curves.
One hundred and three consecutive patients were classified as having virus-like (48), bacterial (37) and unknown
(18) pneumonia, respectively. Independent predictors related to bacterial pneumonia were an acute onset of
symptoms (OR 31; 95% Cl, 6–150), age greater than 65 or comorbidity (OR 6?9; 95% Cl, 2–23), and leukocytosis
or leukopenia (OR 2; 95% Cl, 0?6–7). The sensitivity and specificity of the scoring system to identify patients with
bacterial pneumonia were 89% and 94%, respectively. The prediction rule developed from these three variables
classified the aetiology of pneumonia with a ROC curve area of 0?84.
Proper use of basic clinical and laboratory information is useful to identify the aetiology of CAP. The prediction
rule may help clinicians to choose initial antibiotic therapy.
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Community-acquired pneumonia (CAP) is one of the most
common infectious diseases treated in ambulatory and
hospital settings, and is associated with significant morbid-
ity and mortality (1).
Traditionally, physicians have used information obtained
from the history to select the initial antibiotic therapy in
patients with CAP. However, previous studies have
suggested that this information has a low sensitivity and
specificity to predict the aetiology (2).Received 20 July 1999 and accepted in revised form 15 December
1999.
Correspondence should be addressed to: Agustı´n Ruiz-Gonza´lez,
MD, C/Balmes 3-3B, 25006 Lleida, Catalonia, Spain.
0954-6111/00/050505+06 $35?00/0We developed a prospective study with the aim of
establishing the aetiology of CAP in our area. The
microbial findings were then compared with information
obtained from the history to determine whether the initial
presentation can accurately predict the aetiology of CAP.
Methods
DATA COLLECTION
During a 15-month period from 1 January 1993 to 31
March 1994, demographic information and data on co-
morbidity, symptoms, signs, laboratory and chest radio-
graphic findings were collected prospectively from
consecutive patients 14 years of age or older admitted to
the Emergency Department at the University Hospital# 2000 HARCOURT PUBLISHERS LTD
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study, patients had to have a principal diagnosis of
pneumonia according to the International Classification
of Disease, 9th Revision, Clinical Modification (ICD-9-
CM) (3). We excluded patients who had been hospitalized
within 7 days previous to the current admission or
transferred from another acute care hospital. Clinical
information was recorded on a standardized data form by
the examining physician at the patient visit. Radiographic,
laboratory and microbiological findings were recorded by
investigators during follow-up.
MICROBIOLOGIC STUDIES
Two blood cultures were performed in all patients. Samples
from lung parenchyma were also obtained by transthoracic
needle aspiration (TNA) in patients without contraindica-
tions and after informed consent (4). In addition to
conventional microbial testing, PCR tests to detect
Streptococcus pneumoniae, Mycoplasma pneumoniae, Chla-
mydia pneumoniae and Legionella penumophila DNA were
performed in TNA samples (5–8). Serologies on days 1 and
30 were performed to detect Influenza A virus, Coxiella
burnetii, Chlamydia psittaci (complement fixation test), L.
pneumophila (immunofluorescence test) and C. pneumoniae
(microimmunofluorescence test) antibodies. If available, a
sputum sample was stained and cultured.
Criteria for definitive microbial diagnosis were (i) blood,
pleural or TNA culture yielding a pathogen; (ii) positivity
of S. pneumoniae antigen detection test in TNA sample; (iii)
positivity of PCR test for S. pneumoniae,M. pneumoniae, C.
pneumoniae or L. pneumoniae in lung sample; (iv) a sputum
culture yielding L. pneumophila; (v) a four-fold rise in
antibody titers for M. pneumoniae, C. pneumoniae, C.
psittaci, L. pneumophila, C. burnetii or influenza A virus, or
a single IgG titre of 4512 for C. pneumoniae antibodies.
CLASSIFICATIONS OF THE CATEGORY OF
PNEUMONIA
According to microbial findings, patients were classified
into the following categories of pneumonia (9):
1. Bacterial pneumonia (BP): pneumonia caused by S.
pneumoniae and other pyogenic bacteria (streptococci, H.
influenzae, Staphylococcus aureus and Enterobacteraceae).
2. Virus-like pneumonia (VP): pneumonia caused by M.
pneumoniae, C. pneumoniae, C. psittaci, C. burnetii, L.
pneumophila and virus.
3. Pneumonia of unknown aetiology: pneumonia in which
all microbial work up provided negative results.
DATA PROCESSING AND SATISTICAL
ANALYSIS FOR PREDICTION RULE
Patients with BP or VP were analysed. In step 1, basic
information commonly used by clinicians in the manage-
ment of respiratory infections and easy to obtain at bedside
were first compared by univariate analysis in both groups.The following eight variables were analysed: age, co-
morbidity, white blood cell count, and five variables related
to initial clinical presentation [acute onset (less than a 24-
period), chills, pleuritic chest pain, production of purulent
sputum, and signs of consolidation at auscultation] (10).
Candidate predictor variables were converted to dichot-
omous variables and classified into three categories:
epidemiological (the presence or absence of age greater
than 65 or co-morbidity), clinical (the presence or absence
of the symptoms and signs above described), and biological
(the presence or absence of an abnormal white blood cell
count, defined as leukocytosis 116109 l71 or leukopenia
46109 l71). In step 2, only variables found to be
statistically significant were included in a score system.
According to the odds ratio assigned, adjusted by a logistic
regression model, variables were scored in a scale from 0 to 5.
Comparison of variables among patients with dierent
aetiologies was made by using chi-square with Yates’
correction for continuity. All values of less than 0?05 were
considered significatives. Sensitivity and specificity were
calculated according to standard methods (11). Confidence
intervals of 95% were used. The accuracy of the scoring
model in discriminating the aetiology of pneumonia was
evaluated by using the area under receiver operating
characteristic (ROC) curve (12).
Results
PATIENT DEMOGRAPHICS
The final study population was constituted by 103 patients.
The mean age was 51years (15–87). Forty-one (39?8%) were
older than 65 years, and 35 (85?3%) come from their home.
The male–female ratio was 1:38. Thirty-seven (35?9%)
patients had co-morbidity (chronic bronchitis: 11; HIV
infection: eight; chronic heart failure: seven; malignancy:
four; chronic liver disease: three; diabetes: two; stroke: one;
dementia: one). Respiratory failure (PaO2560mmHg) was
present in 45 (43?6%) patients. Seventy-seven (74?7%)
required hospitalization and three (4%) of them died.
AETIOLOGY OF PNEUMONIA
A definitive aetiological diagnosis was established in 85
(82?5%) patients. According to methods, patients were
classified into having the following categories of pneumo-
nia: (a) virus-like pneumonia: 48 (46?6%): Chlamydia spp:
21; Mycoplasma: 20; virus: five; C. burnetii; two; (b)
bacterial pneumonia: 37 (35?9%): S. pneumoniae: 27; H.
influenzae: seven; Streptococcus viridans: one; Streptococcus
pyogenes; one; Enterococcus faecium: one; (c) Pneumonia of
unknown aetiology: 18 (17?4%).
ANALYSIS OF DATA AND DEVELOPMENT
OF THE SCORING SYSTEM
Comparison of basic epidemiological, clinical and biologi-
cal variables between groups is shown in Table 1.
TABLE 1. Comparison of variables between categories of pneumonia and development of the scoring system
Bacterial
pneumonia
n=37 %
Virus-like
pneumonia
n=48 (%)
P-value OR*
(95% CI)**
Score
Epidemiological
Age 465 or co-morbidity 25 (68) 12 (25) 50?05 6?9 (2–23) 3
Clinical
Acute onset 28 (76) 10 (21) 50?05 31 (6–150) 5
Chills 11 (31) 9 (19) 0?23 0?4 (0?1–1?6)
Chest pain 25 (68) 23 (48) 0?07 0?8 (0?2–2?6)
Purulent sputum 10 (27) 11 (23) 0?66 2?4 (0?6–9?1)
Signs of consolidation 25 (68) 30 (63) 0?62 0?5 (0?1–2)
Biological
Leukocytosis or leukopenia 30 (81) 20 (41) 50?05 2 (0?6–7) 2
*OR=odds ratio.**Cl=confidence interval.
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older than 65 years of age or had a higher rate of
comorbidity (68% vs. 25%; OR 6?9, 95% CI 2–23) and
had abnormal white blood cell counts (81% vs. 42; OR 2,
95% CI 0?6–7). Among clinical variables only an acute
onset of symptoms was statistically related to BP (76% vs.
21%; OR 31, 95% CI 6–150).
According to the level of the odds ratio assigned,
independent variables were scored as follows: an acute
onset of symptoms: five; an age greater than 65 years or
comorbidity: three; leukocytosis or leukopenia: two (Table
1). After examining the clinicians priorities, several cut-o
points were suggested: (a) when sensitivity in detecting BP
patients was considered the end-point, a cut-o point of 5
was selected (sensitivity: 89%; specificity: 63%) (Table 2),
and 85 (100%) patients could be classified; (b) when
specificity of the scoring system was required, two cut-o
points were selected: a score of 10 as specific point to
identify BP patients (sensitivity: 57; specificity: 94%), and a
score of 3 as a specific point to identify VP patients
(sensitivity: 63%, specificity: 89%) (Table 2), and 58 (68%)
patients could be classified. The area under the ROC curve
was 0?84 (Fig. 1).
Discussion
The results of this study show that among patients with
CAP, the aetiology of pneumonia could be discriminated
on the basis of findings obtained from the history, physical
examination and basic laboratory information. A predic-
tion rule derived from data traditionally used by clinicians
in the management of CAP such as age, comorbidity, the
clinical presentation and white blood cell count, classified
the aetiology of patients with a ROC curve area of 0?84,
indicating good discrimatory power (13).
The specific aetiologic diagnosis in CAP patients is often
delayed for several days until the results from sputum andblood cultures are available. Although Gram stain has been
widely performed to provide rapid information on the
aetiology of pneumonia there is limited evidence of its
usefulness (14,15). In addition, serology is available for
many respiratory pathogens, but it does not often provide
diagnostic changes early enough to be clinically useful. In
this situation, clinicians have tried to obtain information
from the history to select the initial antibiotic therapy for
the most likely pathogen.
This traditional practice has been questioned by the
results of previous studies that have failed to find a
relationship between clinical presentation and the pathogen
responsible (16,17). The study by Farr et al. (16), provided
a quantitative estimation of the diculty on predicting the
microbial aetiology on the basis of the presenting symptoms
and signs at admission to hospital. They found that the four
main categories of pneumonia (pneumococcal, mycoplas-
ma, other and undetermined) could be predicted in only
42% of the patients. However, the use of unspecific
microbial diagnostic criteria such as sputum culture and
probably, a partial overlap of the categories, may explain
the low discriminatory power of the prediction model. In
other study, Fang et al. (17) did not find dierences at
presentation between pathogens causing pneumonia. How-
ever it must be said that 67% of patients included in the
analysis has only a presumptive microbial diagnosis, and
patients with pneumonia due to M. pneumoniae were
inexplicably excluded.
In our study, we have tried to avoid the methodological
limitations found in previous studies. First, only samples of
undoubted specificity were analysed. Thus the sputum was
changed for lung samples obtained by TNA, which has
previously showed to have a high specificity in the study of
lung infection (18–19). Second, the variables included in the
study were carefully selected. Only basic clinical and
biological information traditionally used in the manage-
ment of respiratory infections and easy to obtain at bedside
prior to antibiotic therapy being started, were included in
TABLE 2. Sensitivity and specificity of several cut-o points suggested
End-point Score Sensitivity
% (95% CI*)
Specificity
% (95% CI*)
Identification of
patients with bacterial
pneumonia
5 89 (78–96) 63 (54–81)
Identification of
patients with bacterial
pneumonia
10 57 (40–74) 94 (86–100)
Identification of
patients with virus-like
pneumonia
3 63 (48–77) 89 (78–100)
*CI=confidence interval.
FIG. 1. Receiver-operating-characteristic curve for the combined score of the three epidemiological, clinical and laboratory
variables. The zone to the left of the thick line indicates a high probability of bacterial pneumonia (score 10, specificity 94%).
The zone to the right of the thin line indicates a high probability of virus-like pneumonia (score, 53, specificity 89%).
508 A. RUIZ-GONZA´LEZ ET AL.the prediction rule. Although radiographic findings have
shown to be of some use in prediction of the aetiology of
pneumonia (20), no attempt was made to include the chest
radiograph in the analysis because problems in accesibility
and interpretation to such a test (21). Third, a clinical
usefulness of the prediction rule was a priority in the design
of our analysis. It has been suggested that one of the main
issues in the management of respiratory infections is to
discriminate whether the pathogen belongs to either a
bacterial a virus-like category in order to select either
betalactamic or macrolide therapy, and our study con-
tributes to solving this issue (9,22).
Previous studies have already found some distinct
features between patients with CAP. Elderly and the
presence of chronic conditions have been related to
bacterial pathogens (23), and pneumonia due to Myco-
plasma has been often diagnosed in young healthy
populations (24). In addition, a higher rate of sputumproduction, pleuritic chest pain and leukocytosis have
previously shown a tendency to be caused by S. pneumoniae
(17,25). In a recent study (26), diarrhoea and increase
creatine kinase was found to predict L. pneumophila
pneumonia in the Emergency Department and
proposes that, based on this information, clinicians should
prescribe a macrolide antibiotic and apply rapid confirma-
tory tests. However, as recently suggested (27), there is little
information in the literature of whether a constellation of
variables can predict the aetiology of pneumonia. In a
previous study (28), the presence of a combination of
variables (cardiovascular chronic disease  an acute onset
 pleuritic chest pain  leukocytosis  Gram-positive
bacteria in the sputum Gram stain) identified 80% of
infections due to S. pneumoniae. However, the need for
microbiological study of respiratory sample makes this
approach dicult to perform at bedside. Our score system
was developed with the aim of selecting variables easy to
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started.
The results of the present study may also help to solve
this issue. The prediction rule based on the three main
variables (epidemiological, clinical and biological) can be
used as a sensitive or specific test depending on clinician’s
priorities. Thus, when a high specificity is required, two cut-
o points are suggested: when a score of 10 is achieved (for
example, age grater than 65  an acute onset 
leukocytosis), BP is the most likely aetiology (specificity
94%); when a score of 3 is achieved (for example, none of
the variables are present), VP is the most likely aetiology
(specificity 89%). Otherwise, when a high sensitivity is
required, we suggest a score of 5 (for example, an acute
onset, or age greater than 65  leukocytosis). In this
situation, the test identifies a high rate of patients with BP
(sensitivity 89%).
We must address the potential limitations of our
prediction rule before recommending its use in clinical
practice. First, the analysis was performed in adults who
presented to an Emergency Department for CAP therefore,
some patients needed hospitalization (75%) and others
were managed at home (25%). In our opinion, the
prediction rule should be recommended to the same
heterogeneous population. Thus, the introduction of the
prediction rule in other populations would alter the power
of discrimination. However, to have found dierences
between the aetiologies of pneumonia in such a hetero-
geneous sample would probably increase the model’s
robustness and generalizability to other clinical settings.
The validation of this model in other samples could be
solved this issue. Second, it has been suggested that
concerns in predicting the aetiology in patients with
CAP may arise from the fact that infections due to
Legionella can have an overlap of features that
includes both ‘typical’ and ‘atypical’ findings (2). This
issue has not been solved in our study because we had no
cases due to this microorganism. However, because CAP
due to Legionella ranged widely depending on the
geographic area studied (29), we suggest the incorporation
of the prediction model in settings where Legionella
infection is not currently considered. Finally, the score
system developed from the study achieves good specificity
rates at the expense of poor sensitivities. This means that
certainty in identifying patients with bacterial pneumonia
(score 10, specificity 94%) is achieved in only half of these
cases (score 10, sensitivity 57%). Therefore, one should
keep in mind that the score system may be useful in only a
subset of patients.
In conclusion, among adults presenting with CAP, a
prediction rule based on initial presentation accurately
discriminated the aetiology of pneumonia. Recent guide-
lines (30) recommend the use of betalactam antibiotics as
the therapy of choice in patients with lower tract
respiratory infections and, in those with suspected infection
due to atypical agents, macrolides should be then chosen.
The incorporation of the prediction rule to clinical practice
could help clinicians to choose or simplify (from biterapy to
monoterapy) initial therapy in some cases. Further studies
of validation in larger populations are needed.Acknowledgements
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